Abstract:Combination therapy via stimulus-responsive drug release is known to improve treatment efficacy and minimize side effects. However, the use of low-abundance cancer biomarkers as molecular triggers to induce efficient drug release for combination therapy still remains a challenge. Herein, we developed a dual microRNA-responsive drug nanocarrier for catalytic release of doxorubicin (Dox) and small interfering RNA (siRNA) in cancerous cells for combined chemotherapy and gene therapy with logic operation. The nanocarrier is constructed by assembling two duplexes of DNA/RNA and Dox molecules onto DNA-functionalized gold nanoparticles. Two microRNA molecules (miRNA-21 and miRNA-10b overexpressed in MDA-MB-231) could alternatively catalyze the disassembly of the nanocarrier through a thermodynamically driven entropy gain process, during which Dox molecules are released, and the two pairs of released DNA/RNA duplex hybridize to generate siRNA (siBcl-2) in situ by strand displacement reactions. Quantum dots are used to track the process in living cells. The AND logic gate-based drug release system allows effective treatment of specific cancer cell types according to miRNA expression patterns. This strategy represents an effective means to overcome multidrug resistance and improve therapeutic effects.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c09494?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c09494</a>.Materials and methods including characterization of GNPs (Figure S1), characterization of DNA2-QD (Figure S2), characterization of DNA hybridization (Figure S3), PAGE analysis of the strand displacement reaction (Figure S4), FL and ICP data for determination of the D1D′1C and D2DQ number (Figure S5), characterization of catalytic disassembly of Dox-GNC (Figure S6), stability test of Dox-GNC (Figure S7), agarose gel electrophoresis characterization of disassembly of GNC (Figure S8), determination of Dox loading on GNC (Figure S9), specificity of Dox-GNC triggered by dual miRNAs for drug release (Figure S10), stability of GNC at physiological circumstances (Figure S11), cell viabilities of three cell lines treated with GRR-Dox in the presence or absence of fuel DNA for different times (Figure S12), cell viabilities of MDA-MB-231 cells transfected with waste DNA (Figure S13), cell viabilities of MDA-MB-231 cells under different treatments (Figure S14), and expression level of the Bcl-2 protein measured with western blot (Figure S15) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c09494/suppl_file/am0c09494_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

A Microrna-21-responsive Doxorubicin-Releasing Sticky-Flare for Synergistic Anticancer with Silencing of Microrna and Chemotherapy

Fluorescent detection of microRNA-21 in MCF-7 cells based on multifunctional gold nanorods and the integration of chemotherapy and phototherapy

Sequential Co-Delivery of Mir-21 Inhibitor Followed by Burst Release Doxorubicin Using NIR-responsive Hollow Gold Nanoparticle to Enhance Anticancer Efficacy

MicroRNA-Responsive DNA-Programmed Nanomedicine with Controllability of Cascaded Events for Cancer Therapy Enhancement

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Near Infrared-Guided Smart Nanocarriers for MicroRNA-Controlled Release of Doxorubicin/siRNA with Intracellular ATP As Fuel.

Gold Nanorods Electrostatically Binding Nucleic Acid Probe for In Vivo MicroRNA Amplified Detection and Photoacoustic Imaging-Guided Photothermal Therapy

MicroRNA-Responsive Cancer Cell Imaging and Therapy with Functionalized Gold Nanoprobe.

In Situ Amplification of Intracellular Microrna with Mnazyme Nanodevices for Multiplexed Imaging, Logic Operation, and Controlled Drug Release

A Cancer Cell Membrane Coated, Doxorubicin and Microrna Co-Encapsulated Nanoplatform for Colorectal Cancer Theranostics

Dual MicroRNA-Triggered Drug Release System for Combined Chemotherapy and Gene Therapy with Logic Operation

Upconversion Nanoparticle@Au Core-Satellite Assemblies for in Situ Amplified Imaging of MicroRNA in Living Cells and Combined Cancer Phototherapy

A nanoprobe for fluorescent monitoring of microRNA and targeted delivery of drugs

A telomerase-responsive nanoprobe with theranostic properties in tumor cells

MUC-1 Recognition-Based Activated Drug Nanoplatform Improves Doxorubicin Chemotherapy in Breast Cancer.

Are children too young for mental disorders?

[Metabolism of carbohydrates; action of insulin on formation of alcohol from enzymes of animal origin].

Endogenous MicroRNA-Triggered and Real-Time Monitored Drug Release Via Cascaded Energy Transfer Payloads

A Targeted DNAzyme-Nanocomposite Probe Equipped with Built-in Zn2+ Arsenal for Combined Treatment of Gene Regulation and Drug Delivery

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

The Promising Nanocarrier for Doxorubicin and Sirna Co-delivery by PDMAEMA-based Amphiphilic Nanomicelles.